Form 4: Pfizer Executive Modifies Stock Appreciation Rights in Shareholder Return Unit Program
SEC Form 4
Payal Sahni, an Executive Vice President at Pfizer, modified stock appreciation rights (TSRUs) to extend their vesting and settlement dates by two years, as part of a one-time offer by the issuer.
Summary
- Payal Sahni, an Executive Vice President at Pfizer, filed a Form 4 to report changes in beneficial ownership.
- The changes relate to the modification of stock appreciation rights (TSRUs) under Pfizer's one-time Modification Offer.
- Sahni elected to modify certain outstanding TSRUs to extend their vesting and settlement dates by two years.
- The grant price and number of shares underlying the Modified TSRUs remain unchanged.
- The modification affects 45,920 TSRUs originally set to expire on 02/23/2028, now expiring on 02/23/2030, and 42,265 TSRUs originally set to expire on 02/24/2027, now expiring on 02/24/2029.
- The modification was made on 09/12/2024.
Sentiment
Score: 6
Explanation: The document is neutral in tone, simply reporting a standard executive compensation adjustment. There are no indications of significant positive or negative implications for the company's performance.
Positives
- The modification offer provides eligible participants the opportunity to extend the dates upon which the awards vest and settle by two years.
Future Outlook
The document does not contain specific forward-looking statements beyond the details of the TSRU modification.
Industry Context
This filing reflects standard executive compensation practices within large publicly traded companies, where stock appreciation rights are used to align executive incentives with shareholder value. The modification offer suggests a strategic approach to managing long-term incentives.
Comparison to Industry Standards
- Stock appreciation rights are a common component of executive compensation packages in the pharmaceutical industry, similar to companies like Johnson & Johnson, Merck, and AbbVie.
- The vesting schedules and modification offers are often tailored to align with long-term strategic goals, which is a practice seen across various large-cap companies.
Stakeholder Impact
- The modification of TSRUs could potentially impact shareholder value over the long term by influencing executive behavior.
- The modification of TSRUs could potentially impact employee morale.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Pfizer filed the Tender Offer Statement on Schedule TO with the SEC. |
| 09/12/2024 | Date of the transaction where Payal Sahni modified the Stock Appreciation Rights. |
| 09/16/2024 | Date of the Form 4 filing. |
| 02/23/2028 | Original expiration date of 45,920 TSRUs before modification. |
| 02/23/2030 | New expiration date of 45,920 TSRUs after modification. |
| 02/24/2027 | Original expiration date of 42,265 TSRUs before modification. |
| 02/24/2029 | New expiration date of 42,265 TSRUs after modification. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.